Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
- Carey, Jason P. W.
- Yi, Min
- Wang, Jing
- Rao, Xiayu
- Liu, Bin
- Ha, Min Jin
- Kohansal, Mehrnoosh
- Bui, Tuyen
- Vijayaraghavan, Smruthi
- Kettner, Nicole M.
- Chen, Xian
- Eckols, T. Kris
- Raghavendra, Akshara S.
- Ibrahim, Nuhad K.
- Karuturi, Meghan Sri
- Watowich, Stephanie S.
- Sahin, Aysegul
- Tweardy, David J.
- Hunt, Kelly K.
- Tripathy, Debu
- Keyomarsi, Khandan
- Durak, MERİH
Publication date
July 2019
DOI Publisher
American Association for Cancer Research (AACR)Abstract
Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor-positive, HER2-negative breast cancer. Although this treatment doubles time to progression compared with endocrine therapy alone, about 25%-35% of patients do not respond, and almost all patients eventually acquire resistance. Discerning the mechanisms of resistance to CDK4/6 inhibition is crucial in devising alternative treatment strategies
Add to ORKG